Status:
UNKNOWN
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
Lead Sponsor:
Shanghai Public Health Clinical Center
Conditions:
Coronavirus
Eligibility:
All Genders
Brief Summary
There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the CO...
Eligibility Criteria
Inclusion
- The participants were diagnosed as COVID-19;
- Participants received anti-SARS-CoV-2 inactivated convalescent plasma
- Written the informed consent.
Exclusion
- Participants lacked detailed medical history
Key Trial Info
Start Date :
February 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04292340
Start Date
February 1 2020
End Date
December 31 2020
Last Update
March 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China, 201508